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Abstract
Background: Overdiagnosis in cancer screening is the detection of cancer lesions that would
otherwise not have been detected. It is arguably the most important harm. We quantified
overdiagnosis in the Danish mammography screening programme, which is uniquely suited for this
purpose, as only 20% of the Danish population has been offered organised mammography screening
over a long time-period.
Methods: We collected incidence rates of carcinoma in situ and invasive breast cancer in areas
with and without screening over 13 years with screening (1991-2003), and 20 years before its
introduction (1971-1990). We explored the incidence increase comparing unadjusted incidence
rates and used Poisson regression analysis to compensate for the background incidence trend,
variation in age distribution and geographical variation in incidence.
Results: For the screened age group, 50 to 69 years, we found an overdiagnosis of 35% when we
compared unadjusted incidence rates for the screened and non-screened areas, but after
compensating for a small decline in incidence in older, previously screened women. Our adjusted
Poisson regression analysis indicated a relative risk of 1.40 (95% CI: 1.35-1.45) for the whole
screening period, and a potential compensatory drop in older women of 0.90 (95% CI: 0.88-0.96),
yielding an overdiagnosis of 33%, which we consider the most reliable estimate. The drop in
previously screened women was only present in one of the two screened regions and was small in
absolute numbers.
Discussion: One in four breast cancers diagnosed in the screened age group in the Danish
screening programme is overdiagnosed. Our estimate for Denmark is lower than that for
comparable countries, likely because of lower uptake, lower recall rates and lower detection rates
of carcinoma in situ.
Background
Overdiagnosis in cancer screening is defined as the detec-
tion of cancers that would otherwise not have been
detected in the remaining life-span of the individuals [1].
It is mainly caused by the detection of slow-growing can-
cers that do not manifest clinically before people die from
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other causes [2], but may also be due to identification of
borderline malignancies, or cancers that were bound to
regress [3,4].
Overdiagnosis is arguably the most important harm of
screening, as healthy people are being diagnosed with and
treated for cancer unnecessarily, which carries great per-
sonal costs, both physically and psychologically [2].
Overdiagnosis is an unavoidable consequence of mam-
mography screening [2]. It is also well documented for
other cancers, e.g. lung cancer, neuroblastoma and pros-
tate cancer [5]. Although about 60% of men in their 60's
have cancer lesions in their prostate in autopsy studies,
the observed incidence is much smaller and the lifetime
risk of dying from prostate cancer is only 3% [5]. Some of
these otherwise undetected cancers will become diag-
nosed if screening is implemented, and this is an impor-
tant reason that screening for prostate cancer is
discouraged in many Western countries [5]. Overdiagno-
sis is also a problem with mammography screening, but it
has been been omitted in most information material
intended to help women make informed decisions about
participation [6-8].
Overdiagnosis in mammography screening has been doc-
umented in systematic reviews of the randomised trials.
Screening led to a 31% increase in the use of breast cancer
surgery, which included a 20% increase in the use of mas-
tectomies [9]. We have recently quantified the extent of
overdiagnosis in breast cancer screening programmes in
Manitoba, New South Wales, Norway, Sweden and the
UK and found 52% overdiagnosis, including carcinoma
in situ lesions (CIS) [10]. There were large and sustained
increases in breast cancer incidence when screening was
introduced, with only small or absent compensatory
decreases among older, previously screened women. A
compensatory decrease in incidence is required, if the
incidence increase in the screened group is due only to
advancement of the time of diagnosis (lead-time) [11].
Data on CIS lesions are often lacking in articles that
describe indicence trends [10], although CIS is mainly
diagnosed through screening and contributes substan-
tially to overdiagnosis, as these lesions currently consti-
tute 20% of breast cancers detected at screening in the UK
and more in the USA [12,13], and although less than half
of them progress to invasive breast cancer [2]. A limitation
of our systematic review was that there were no concomi-
tant control groups without screening and we therefore
used linear projections of pre-screening rates to estimate
the overdiagnosis [10].
Estimating overdiagnosis can be particularly difficult in
countries that do not have an organised screening pro-
gramme and therefore have no well-defined pre- and post-
screening period, e.g. the USA. Also, in the USA, there is
no control group without screening, as all areas have
screening in private practices. Comparisons with younger
and older age groups is also unreliable in this case, as
women are recommended to be screened from they are
very young, and as there is no upper age limit. Contrary to
this, the Danish breast cancer screening programme pro-
vides a unique opportunity for estimating overdiagnosis,
as there has been a period of 17 years (1991-2007) where
only about 20% of potentially eligible women have been
invited to screening with mammography, in two separate
administrative regions, with a well-defined target age
group and starting point. Partly because of an intensive
debate about the balance between the benefits and harms
of screening, the Danish administrative regions have pri-
oritised their resources differently. A national screening
policy has now been adopted and is currently being
implemented.
We compared breast cancer incidence in areas with and
without organised screening. We studied whether the
increase in incidence in women who were offered screen-
ing was compensated by a drop in breast cancer incidence
when the women passed the age limit for screening, and
compared with the development in women in the same
age group in areas without screening, and with that in
younger women. We corrected the estimates of overdiag-
nosis for differences in age distribution, geographical dif-
ferences in pre-screening incidence rates and changes in
background incidence with Poisson regression analyses.
Methods
We retrieved data on breast cancer incidence in females
during 1971-2003 from the Danish Cancer Registry at the
National Board of Health (data were not yet available for
2004-2007). The data we received were aggregated by geo-
graphical region and into 5-year age groups. Data on pop-
ulation size for each year, region and age group were
obtained from Statistics Denmark [14]. We included car-
cinoma in situ, as these lesions are treated surgically as if
they were invasive cancers.
Organised mammography screening of women aged 50-
69 years began April 1st 1991 in Copenhagen municipal-
ity, November 1st 1993 in Funen County, and June 1st
1994 in Frederiksberg municipality. The Frederiksberg
programme, which comprised comparatively few women,
was incorporated into the Copenhagen programme Janu-
ary 1st 1997 [15]. In 2003, there were 115,270 women
aged 50-69 years old in the screened areas (54,933 in
Copenhagen and Frederiksberg and 60,337 in Funen),
and 551,778 in areas without organised screening [14].
The attendance rates were 63% in Copenhagen and 83%
in Funen in the fourth screening round [16], which areBMC Women's Health 2009, 9:36 http://www.biomedcentral.com/1472-6874/9/36
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lower than in Sweden, Norway, Finland and the UK [2].
The recall rates per incidence round were 4.3% in Copen-
hagen and 1.3% in Funen [15], which are also lower than
in comparable countries.
The population in Copenhagen and Funen is comparable
with the rest of Denmark regarding age distribution and
socioeconomic status. Copenhagen is the largest city, but
the second largest is in the non-screened areas, and there
are rural areas in Funen County, like in the rest of Den-
mark. The Danish population is one of the most homog-
enous in the world.
We first explored the incidence increase using the
observed rates, without adjustments. We calculated the
average incidence rate ratio between screened and non-
screened areas for the screened age group. We then sub-
tracted the compensatory decline in older, previously
screened women (ages 70-79 years) to estimate overdiag-
nosis, after calculating the absolute number of diagnoses
that the incidence rates corresponded to. Two years after
screening was introduced, women aged 70 and 71 would
have been offered screening once, as women are called for
screening every second year. After four years, women aged
72 and 73 would have been offered screening once, and
women aged 70 and 71 would have been offered screen-
ing twice. After 10 years, all women would have been
offered screened previously (which is in 2001 in Copen-
hagen and in 2003 in Funen), with the younger ages hav-
ing been offered screening more than once. We would
therefore expect to see a trend towards declining incidence
in the age group 70-79 years, beginning early on after the
onset of screening. We also used simple linear regression
to estimate incidence trends before and after the introduc-
tion of screening [10].
We used Poisson regression analyses to obtain more relia-
ble estimates of overdiagnosis, with confidence intervals,
and adjusted for differences in age distribution using 5-
year age groups, and for the fact that Funen introduced
screening 3 years after Copenhagen, and for geographical
differences in incidence, using the pre-screening period as
reference.
We also used Poisson regression analysis to quantify the
compensatory drop in incidence in women ages 70-79
years. The Poisson regression model was adjusted only for
age and included a trend parameter, starting in 1998,
because 7 in 10 women in Copenhagen in this age group,
and 4 in 10 women in Funen, would then have been
offered screening previously. We used the incidence in the
rest of Denmark as reference to compensate for the
increasing background incidence in this age group.
The statistical analyses were performed using Egret version
2.0.3 and graphs were made in Microsoft Excel 2000.
Results
Data were available from 13 years of organised mammog-
raphy screening (1991-2003). In women aged 50-69
years, 5,189 cases of breast cancer (of which 6% were CIS)
were diagnosed during 1,342,836 woman-years in areas
offering screening (average 386/100,000 woman-years),
and 17,686 cases (3% CIS) were diagnosed during
6,191,609 woman-years in areas not offering screening
(average 286/100,000 woman-years) (Table 1).
Among women in the screened age group, pre-screening
breast cancer incidence increased at a stable rate from
1971-1990 (Fig. 1), with slightly higher rates in the
screened areas than in the non-screened areas (average
214 vs. 198 breast cancers per 100,000 person-years)
(Table 1). There were also slightly higher rates in the
screened areas in the age groups 35-49 years and 70-79
years in this period (Table 1).
The breast cancer incidence doubled in Copenhagen in
1991 and in Funen in 1994, when screening was intro-
duced (Fig. 1). After the first round of screening, the breast
cancer incidence in screened areas was about 30% higher
than in the non-screened areas, and more when compared
with the expected incidence projected from the pre-
screening incidence. Using a linear regression analysis for
the screened areas for the incidence rounds 1996-2003,
there were 36% more breast cancers than expected in
2003 in the screened areas (Fig. 1). In the non-screened
areas, the breast cancer incidence was also somewhat
higher than expected (Fig. 1).
The screening activity in the age group 50-69 years is
reflected in the detection rates of CIS (Fig. 2). There were
increases of several hundred per cent in the screened areas,
both compared to the rates in the non-screened areas, and
to expected rates (Fig. 2). Rates of CIS increased somewhat
in the screened areas before the introduction of organised
screening, beginning in 1988 (Fig. 2), likely because of
opportunistic screening.
In the age group 70-79 years, breast cancer incidence also
increased steadily from 1971-1990 (Fig. 3). Breast cancer
incidence in Copenhagen increased more than expected
after the introduction of screening in 1991 (Fig. 3). In
Funen, breast cancer incidence also increased after the
introduction of screening, but there was a drop towards
the end of the observation period (Fig. 3). Breast cancer
incidence in the non-screened areas also increased more
than expected after 1991 (Fig. 3).
In women aged 35-49 years, breast cancer incidence
increased steadily in the period 1971-1990. It then stabi-
lized in Copenhagen and the non-screened areas, but not
in Funen (Fig. 4).BMC Women's Health 2009, 9:36 http://www.biomedcentral.com/1472-6874/9/36
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In the 13 years of screening, there were 1,343 extra breast
cancers detected in the screened areas compared with the
non-screened areas in women aged 50-69 years, when
comparing the unadjusted incidence rates (386 vs. 286
breast cancers per 100,000 women in 1,342,836 woman
years, Table 1), and there were 182 extra cancers detected
in the screened areas collectively, compared with the non-
screened areas, among women aged 70-79 years, i.e. no
compensatory drop (Table 1). The 1,343 extra cancers are
equivalent to 35% overdiagnosis in the screened popula-
tion (Table 2). If we compare only the years 2001-3,
where there was a drop in incidence in Funen among
women aged 70-79 years, there were 255 extra cancers
detected in the age group 50-69 years, 47 of which may
have been compensated. This conservative analysis means
that there were 208 uncompensated extra cancers in the
screened population, or 19% overdiagnosis (Tables 1 and
2). However, the data set is small and random fluctuation
might therefore explain that this estimate is lower than
that for the main analysis.
Poisson regression analyses
In our Poisson regression analysis, where we took poten-
tial biases into account, we found a risk ratio of 2.07 (95%
CI: 1.94-2.21) for the first rounds, and 1.34 (95% CI:
1.29-1.40) in the following period (Table 3). The
weighted average was 1.40 (95% CI: 1.35-1.45).
We found a risk ratio of 0.90 (95% CI: 0.85-0.96) in
women aged 70-79 years in Copenhagen and Funen com-
bined in the period 1998-2003, using Poisson regression
analysis. Using the same model for the age group 70-74
years, where a compensatory drop would appear first and
be most pronounced, we found a risk ratio of 0.89 (95%
CI: 0.80-0.96) (Table 3). We used Poisson regression to
test for a trend towards a linearly accellerating drop in
incidence in women 70-79 years, as such a trend would
increase the likelihood that screening caused the decline.
Again, we chose 1998 as our starting point and repeated
the analysis for the age group 70-74 years to increase the
chance of detection. We did not find such a trend, neither
for the age group 70-79 years (P = 0.50), nor for the age
group 70-74 years (P = 1.00), the annual percentage
change was 0.37% (95% CI: 0.30-0.45).
Forty percent more breast cancers in the screened popula-
tion and a 10% compensatory drop in previously screened
women means that there were 5, 189 - (5,189/1.40) =
1,483 extra breast cancers detected in the period 1991-
2003, and that 2,058 × 0.1 = 206 of these were later com-
pensated (Table 1), which gives 33% overdiagnosis.
Discussion
When we adjusted for regional differences in incidence
and age distribution, and compensated for a decline in
incidence in older, previously screened women, we found
33% overdiagnosis in Denmark. This is lower than the
52% we estimated for other countries in our systematic
review of organised screening programmes, which did not
include Denmark [10]. The likely reasons for this are that
Table 1: Number of breast cancers, number of women, and incidence rates in screened and non-screened areas, before and after 
screening started, and during the last three years of observation.
Screened areas Non-screened areas
1971-1990 No 
screening
1991-2003 
Screening
2001-3 
Screening
1971-1990 1991-2003 2001-3
Breast cancers 35-49 years 2,110 1,684 (4% CIS) 381 (3% CIS) 8,668 7,228 (5% CIS) 1,741 (4% CIS)
50-69 years 5,846 5,189 (6% CIS) 1,282 (6% CIS) 16,263 17,686 (3% CIS) 4,922 (2% CIS)
70-79 years 3,258 2,058(3% CIS) 383 (2% CIS) 7,256 6,483 (2% CIS) 1,767 (2% CIS)
Person years 35-49 years 1,759,614 1,317,024 314,322 7,827,731 6,038,527 1,412,069
50-69 years 2,737,925 1,342,836 326,946 8,223,810 6,191,609 1,565,967
70-79 years 1,195,296 606,034 117,077 2,743,410 2,100,884 481,608
Per 100,000 35-49 years 120 128 121 111 120 123
50-69 years 214 386 392 198 286 314
70-79 years 273 340 327 264 309 367BMC Women's Health 2009, 9:36 http://www.biomedcentral.com/1472-6874/9/36
Page 5 of 10
(page number not for citation purposes)
the Danish screening programme has low recall rates, e.g.
only 1.3% per round in Funen [15], low detection rates
for CIS (6% of diagnoses, Table 1), because of a deliber-
ately conservative attitude towards detection of microcal-
cifications [17], and comparatively low uptake, e.g. 63%
in Copenhagen [16].
We did not take opportunistic screening in the non-
screened areas into account in our Poisson regression
analyses, and we might therefore have underestimated
overdiagnosis. We abstained from this adjustment, as the
level of opportunistic screening in the non-screened areas
is difficult to estimate. Increasing rates of CIS indicate that
there was opportunistic screening in Copenhagen and
Funen from about 1988, but that there was little oppor-
tunistic screening in the rest of Denmark (Fig. 2). Another
study confirmed our findings and estimated that oppor-
tunistic screening outside the organised programme cov-
ered only 10% of the women [18], and noted that it was
difficult to differentiate between diagnostic and screening
mammograms using available statistics. CIS has been
reported to be poorly registered outside the screening pro-
grammes [17] and increased little (Figure 2), whereas the
incidence of breast cancer overall increased more than
expected in the non-screened areas from 1991 (Fig. 1).
This increase is partly due to overdiagnosis caused by
opportunistic screening, but could also partly reflect an
increase in background incidence, although the stable
incidence rates in the age group 35-49 years speak against
this (Figure 4). As we compared screened and non-
screened regions, general changes in the background inci-
dence would not affect our estimate of overdiagnosis,
which is a strength of our study, compared to using pro-
jections of pre-screening incidence rates in the screened
regions only [10,17].
In 2003, at the end of our observation period, practically
all women aged 70-79 years in Copenhagen and Funen
had been offered screening several times at an earlier age
and had therefore contributed to the observed incidence
increase in the age group 50-69 years earlier on. In other
words, the cohort of women aged 70-79 years in 2003
consisted entirely of women who were 60-69 years earlier
on in our observation period and who had therefore been
offered screening previously. In the absence of overdiag-
nosis, the incidence in the age group 70-79 years should
therefore drop more and more with increasing follow-up.
However, there was no drop in incidence rates in Copen-
hagen and it is contrary to screening theory that we failed
to detect a trend towards progressively lower incidence
Unadjusted incidence of in situ and invasive breast cancers per 100,000 women ages 50-69 years in areas without mammogra- phy screening and in Copenhagen and in Funen Figure 1
Unadjusted incidence of in situ and invasive breast cancers per 100,000 women ages 50-69 years in areas with-
out mammography screening and in Copenhagen and in Funen.
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rates in previously screened women [11]. There was a drop
in Funen after about 7 years with screening (Fig. 3), but as
there were fewer breast cancers in Funen, and as the inci-
dence increased more than expected in this age group in
Copenhagen, the combined drop is negligible. A compen-
satory drop should have occurred earlier in Copenhagen
than in Funen, which speaks against that the drop in
Funen is related to screening. We consider it unlikely that
longer follow-up would change these findings, as we were
also unable to demonstrate important compensatory
declines in countries with longer follow up than Denmark
[10]. The data material is small enough that the drop in
Funen could be a random fluctuation and more follow up
is required to establish this. Until this is available, we
therefore consider our conserative estimate of 19% over-
diagnosis based on only the last observation years as less
reliable.
In the screened areas, breast cancer incidence in the age
group 50-69 years was higher than in the age group 70-79
years throughout the period with organised screening
(compare Fig. 1 and 3). Mammography screening has dra-
matically changed the shape of the age-specific breast can-
cer incidence curve: it was increasing with age prior to
screening, but now has a maximum in the age group 50-
69 years. Furthermore, because there are many more
women in the age group 50-69 years than in the age group
70-79 years (ratio 2.3 to 1, see Table 1), the drop in the
incidence rate in the age group 70-79 must be much larger
than the increase in the incidence rate in the age group 50-
69 years, if all the extra breast cancers detected through
screening are to be compensated. Even if no breast cancers
were diagnosed in the age group 70-74 years in 2003, it
would not account for the extra breast cancers detected in
the screened age group. This is not compatible with com-
mon expectations of an average lead-time of 2-3 years
[10,19,20] and indicates that a large part of the observed
incidence increase must be due to other causes.
There were minor differences between the screened and
non-screened regions in pre-screening incidence (Table 1
and 3). Such differences were expected, as large cities com-
prised a greater proportion of the screened areas, and as
breast cancer incidence is generally higher in cities. There
was also a higher incidence in the non-screened areas than
expected from the linear projection of the pre-screening
trend (Figure 2). This is partly due to opportunistic screen-
ing, as discussed above, but could also be due to other fac-
tors that increase the breast cancer risk, such as HRT
(hormone replacement therapy). However, while it is
likely that some women in the non-screened areas would
seek opportunistic screening once it was available to oth-
Unadjusted incidence of in situ lesions only, per 100,000 women ages 50-69 years, in areas without mammography screening  and in Copenhagen and in Funen Figure 2
Unadjusted incidence of in situ lesions only, per 100,000 women ages 50-69 years, in areas without mammogra-
phy screening and in Copenhagen and in Funen.
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ers, there is no good reason why the increase should occur
simultaneously with the introduction of screening if it
were due to HRT. The findings of our recent systematic
review on overdiagnosis also speak strongly against a gen-
eral, non-screening related rise in the background inci-
dence, over the pre-screening trend [10]. In the countries
we studied, the abrupt increase in incidence always
occurred simultaneously with screening, despite the fact
that screening was introduced a decade apart in the vari-
ous countries [10]. Further, the increase was by far most
predominant in the invited age range, despite the fact that
this also varied between countries [10].
We did not compare closed cohorts. Influx of patients to
regions with screening could boost incidence in the
screened age groups and in older age groups, leading to
overestimation of overdiagnosis. However, the mobility
between Danish regions in the age group 50-79 years is
limited, and our findings are in good agreement with
those from comparable countries such as Sweden and the
UK, which has nation-wide screening and can be consid-
ered more similar to a closed cohort [19], and where we
found an overdiagnosis of about 50% [10]. It could be
argued that in the beginning of the observation period fol-
lowing the introduction of screening, we compare a
screened cohort with a women who have never been
offered screening. However, this is not so much a limita-
tion of our cohorts as a choice that allows us to document
if there was a trend towards a decline in the incidence rate
of breast cancer, as the proportion of women in the age
group 70-79 years that had previously belonged to the
screened age cohort of women (women aged 50-69 years)
increased. There was no such trend, and at the end of our
observation period, we compared practically only cur-
rently screened women with previously screened women.
Using only the last observation year would be unreliable,
as the data would be prone to random fluctuations given
our comparatively small sample size.
The absence or the small magnitude of a compensatory
drop in previously screened women we found here, and in
our previous review [10], questions the central premise of
breast cancer screening. It shows that very little of the sur-
plus of cancers observed in the screened age group can be
due to advancement of the time of diagnosis (lead-time)
for lethal cancers where screening might be beneficial.
Previous estimates of average lead-times of 2-3 years
[19,20] must therefore be wrong.
Unadjusted incidence of in situ lesions and invasive breast cancers per 100,000 women ages 70-79 years in areas without mam- mography screening and in Copenhagen and in Funen Figure 3
Unadjusted incidence of in situ lesions and invasive breast cancers per 100,000 women ages 70-79 years in 
areas without mammography screening and in Copenhagen and in Funen.
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It has been suggested by comparison of left- with right-
sided irradiation that radiotherapy may double not only
the mortality from heart disease, but also that from lung
cancer [21], although technological improvements may
have diminished these harms to some extent. Lung cancer
is currently rivalling breast cancer as the leading cancer
related cause of death among women in the Western
world and heart disease is the major cause of death in
women. It is therefore of interest that an effect of screen-
ing on all-cause mortality has not been demonstrated. The
randomised trials were not powered to detect a difference
in all-cause mortality, but as more than half a million
women participated in the trials, this at least indicates a
limited absolute benefit of the intervention [9].
More surprisingly, there is no indication that screening
lowers all-cancer mortality, including breast cancer mor-
tality. The relative risk was 1.00 (95% CI 0.96-1.05) in the
randomised trials [9], although with the commonly stated
30% reduction in breast cancer mortality with screening,
the expected relative risk for all-cancer mortality would be
0.95, which is below the confidence interval of what was
actually found [9].
Svendsen et al. have previously concluded that the Danish
data do not provide evidence of overdiagnosis of invasive
breast cancer, or that it was of limited magnitude [17]. The
authors reported that the observed incidence rate in the
screening period in Copenhagen and Funen, considered
separately from each other, was within the 95% confi-
dence interval of the expected rate, which they projected
from the pre-screening rates using regression analysis. Our
linear regression analysis of the pre-screening rates in the
two screening regions combined indicated that a total of
Unadjusted incidence of in situ and invasive breast cancers per 100,000 women ages 35-49 years in areas without mammogra- phy screening and in Copenhagen and in Funen Figure 4
Unadjusted incidence of in situ and invasive breast cancers per 100,000 women ages 35-49 years in areas with-
out mammography screening and in Copenhagen and in Funen.
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Table 2: Number of extra cancers in screened women (ages 50-69 years), number of extra cancers compensated in previously 
screened women (ages 70-79 years), and unadjusted estimates of overdiagnosis in Denmark.
1991-2003 2001-3
Extra breast cancers 1,343 255
Cancers compensated in women aged 70-79 years None (182 surplus cancers) 47
Overdiagnosed breast cancers 1,343 208
Overdiagnosis 35% 19%BMC Women's Health 2009, 9:36 http://www.biomedcentral.com/1472-6874/9/36
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3,901 women with breast cancer would be expected,
whereas we observed 5,189 cases during the 1,342,836
woman-years from 1991-2003. This yields an incidence
rate ratio of 1.33, or 33% more breast cancers than
expected, with a 95% confidence interval of 1.28-1.39.
However, Svendsen et al. not only separated calculations
of their confidence intervals for Copenhagen and Funen,
they also calculated the confidence interval for each year
of observation individually. Further, they left out diag-
noses of CIS from their calculations. Thus, by splitting the
data, Svendsen et al. only found a non-significant differ-
ence, and this formed the basis for their conclusion. We
believe the study by Svendsen et al. does not provide evi-
dence against overdiagnosis, and other authors have
excluded it from their review on overdiagnosis [22].
Some of the same authors have previously claimed that,
after the prevalence peak in the first rounds, the breast
cancer incidence in a screened population should decline
rapidly to the level expected without screening, if there
were no overdiagnosis and a closed cohort was studied
[23]. The Danish authors claimed that the incidence
returned to the pre-screening level and that organised
mammography screening could therefore operate without
overdiagnosis [23]. However, they did not present a statis-
tical analysis in support of this and have later published
data for Copenhagen that are compatible with elevated
incidence levels in the screened age group following the
introduction of mammography screening [24].
In another study [20], some of the same authors discussed
complexities in the estimation of overdiagnosis and used
a lead-time model for calculating overdiagnosis in Swe-
den. This is an unreliable approach because current esti-
mates of lead-time disregard overdiagnosis and its
substantial influence on such calculations. Adjusting for
lead-time using these estimates will therefore underesti-
mate overdiagnosis. Most importantly, lead-time models
assume that a very pronounced drop in incidence rates
occurs in previously screened age groups, e.g. a drop of
about 50% has been suggested, based on an assumed
lead-time of 5 years [11]. However, such large drops have
never occurred [10], as we have also shown here for Den-
mark.
Conclusions
The 33% overdiagnosis we found means that one in four
breast cancers diagnosed in a screened population is over-
diagnosed. This is lower than the 52% we have previously
estimated for other mammography screening pro-
grammes, likely because the Danish programme has low
uptake, a deliberately conservative attitude towards
microcalcifications, and low recall rates. Despite these
precautions, the level of overdiagnosis is still disturbingly
high and it leads to overtreatment and great physical and
psychological harms for those who experience it. It is
therefore important that women receive balanced infor-
mation that makes is possible for them to decide on a
rational basis whether screening is right for them. Unfor-
tunately, the official information leaflets women receive
when they are invited to screening do not tell them about
overdiagnosis and overtreatment [8]. We have therefore
published an evidence-based leaflet [25] that has been
translated into several languages, and which conveys the
message that it is not clear whether breast screening does
more good than harm [9].
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